Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KDR R1032Q |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KDR R1032Q | colorectal cancer | sensitive | Cabozantinib | Preclinical - Cell culture | Actionable | In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited reduced ERK phosphorylation and inhibited growth of a colorectal cancer cell line harboring KDR (VEGFR2) R1032Q in culture (PMID: 29588308). | 29588308 | |
| KDR R1032Q | colorectal cancer | sensitive | Lenvatinib | Preclinical - Cell culture | Actionable | In a preclinical study, expression of KDR (VEGFR2) R1032Q in a colorectal cancer cell line resulted in increased sensitivity to Lenvima (lenvatinib), leading to increased growth inhibition in culture (PMID: 29588308). | 29588308 | |
| KDR R1032Q | basal cell carcinoma | predicted - sensitive | Pazopanib | Case Reports/Case Series | Actionable | In a clinical case study, Votrient (pazopanib) treatment in a patient with metastatic basal cell carcinoma harboring KDR R1032Q who had progressed on treatment with Erivedge (vismodegib), resulted in a complete response, but treatment was discontinued after 6 months due to toxic effects, and disease relapse followed 3 months later (PMID: 28384659). | 28384659 |